Tysabri Articles
Stock Commentary - Europe
7 March 2005
Stock Commentary - New York
7 March 2005
Editor's views on Japanese M&A; Tysabri withdrawal
7 March 2005
UPDATE: Biogen and Elan pull MS drug Tysabri from the market on two cases of CNS disorder
7 March 2005
Bioogen and Elan suspend sales of Tysabri
7 March 2005
Biogen/Elan's Tsyabri trial meets endpoint
28 February 2005
Stock Commentary - New York
14 February 2005
Biogen Idec boosted by Avonex
14 February 2005
New product launches in 2004
31 January 2005
Stock Commentary - Europe
22 November 2004
Elan completes $1.5B senior notes offering
22 November 2004
Stock Commentary - Europe
15 November 2004
UPDATE: Serono tops forecasts as EPS rockets 54%
1 November 2004
Stock Commentary - Europe
25 October 2004
Elan denies merger talks with Biogen Idec
25 October 2004
Biogen Idec eyeing up Elan acquisition?
25 October 2004
Elan/Biogen Idec's Antegren filed for Crohn's disease in EU
4 October 2004
Biogen Idec/Elan's Antegren update
23 August 2004
Biogen Idec enters Swiss lion's den
9 August 2004
Elan posts $117.6M 2nd-qtr net loss
9 August 2004
Elan/Biogen's NDA for Antegren accepted
2 August 2004
Stock Commentary - New York
5 July 2004
Priority review for Biogen/Elan's Antegren
5 July 2004
EU filing for Biogen/Elan's Antegren
14 June 2004
Stock Commentary - New York
7 June 2004
Stock Commentary - New York
31 May 2004
Biogen/Elan's Antegren filed for MS in USA
31 May 2004
Biogen Idec's 1st-qtr revenues rise 24%
10 May 2004
Elan/Biogen Idec to file Antegren in EU
29 March 2004
Stock Commentary - New York
1 March 2004
Elan/Biogen Idec's Antegren to be filed for MS early
23 February 2004
Antegren to be studied in RA patients
9 February 2004
Elan/Biogen Idec's Antegren meets goal
9 February 2004
Stock Commentary - New York
4 August 2003
Biogen's profits soar on Avonex turnover
4 August 2003
Lost revenues hit Elan as losses widen further
12 May 2003
Update: Biogen gets US approval for Amevive
10 February 2003
Biogen's Amevive cleared for psoriasis
10 February 2003
Stock Commentary - New York
13 January 2003
Biogen forecasts 20% EPS growth
13 January 2003
Biogen, Elan's Antegren effective in multiple sclerosis
6 January 2003
Biogen Japan product update
19 August 2002
CDP 571 deal with Biogen boosts Celltech
29 April 2002
Elan investing $60 million in Ireland
29 April 2002
Strong earnings growth for Ireland's Elan on healthy US sales
11 February 2002
Biogen forecasts revenues over $1 billion for 2001
7 January 2002
Elan and Biogen initiate Phase III trial for Antegren
7 January 2002
Biogen forecasts revenues over $1 billion for 2001
24 December 2001
Elan and Biogen initiate Phase III trial for Antegren
20 December 2001
Stock Commentary - New York
8 November 2001
Elan and Biogen's Antegren to start Phase III trials in MS
17 September 2001
Elan/Biogen's Antegren promising in Crohn's
31 May 2001
Elan net income leaps 89% in 1st qtr
24 April 2001
Elan full-year 2000 sales top $1.50 billion
29 January 2001
Positive Ph II for Elan/ Biogen's Antegren
24 January 2001
Biogen reports much-anticipated Avonex results in SPMS
18 January 2001
Avonex sales disappoint in USA, according to analysts
11 October 2000
Stock Commentary New York
7 September 2000
Biogen, Elan link up on Antegren antibody
18 August 2000
Liposome and Segix boost Elan revenues
21 July 2000
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
